AMLX - Company ID 0001658551
The table below shows Amylyx Pharmaceuticals, Inc.'s balance sheet line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash & equivalents | $226.65M | $77.39M | $170.20M | $62.53M |
| Short-term investments | $90.33M | $99.11M | $201.16M | $284.42M |
| Receivables | $88.00K | $447.00K | $40.05M | $15.31M |
| Inventory | - | $38.32M | $38.32M | $9.77M |
| Total current assets | $323.67M | $189.43M | $464.67M | $382.13M |
| Property, plant & equipment | $310.00K | $961.00K | $2.69M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $2.61M |
| Goodwill | - | - | - | - |
| Total assets | $332.64M | $193.63M | $517.45M | $391.45M |
| Accounts payable | $3.52M | $2.94M | $22.06M | $6.26M |
| Total current liabilities | $22.69M | $28.41M | $82.04M | $46.61M |
| Long-term debt | - | - | - | - |
| Total liabilities | $27.39M | $28.87M | $84.02M | $50.85M |
| Retained earnings | -$751.43M | -$606.69M | -$304.95M | -$354.22M |
| Total equity | $305.26M | $164.76M | $433.43M | $340.61M |